Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

GIP's involvement in the pathophysiology of type 2 diabetes

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{e274c0f5eb2b45aa8123720adb4a520c,
title = "GIP's involvement in the pathophysiology of type 2 diabetes",
abstract = "During the past four decades derangements in glucose-dependent insulinotropic polypeptide (GIP) biology has been viewed upon as contributing factors to various parts of the pathophysiology type 2 diabetes. This overview outlines and discusses the impaired insulin responses to GIP as well as the effect of GIP on glucagon secretion and the potential involvement of GIP in obesity and bone disease associated with type 2 diabetes. As outlined in this review, it is unlikely that impaired insulinotropic effects of GIP occur as a primary event in the development of type 2 diabetes, but rather develop once the diabetic state is present and beta cells are unable to maintain normoglycemia. In various models, GIP has effects on glucagon secretion, bone and lipid homeostasis, but whether these effects contribute substantially to the pathophysiology of type 2 diabetes is at present controversial. The review also discusses the substantial uncertainty surrounding the translation of preclinical data relating to the GIP system and outline future research directions.",
author = "Christensen, {Mikkel B} and Gasbjerg, {L{\ae}rke S} and Heimb{\"u}rger, {Sebastian M} and Signe Stensen and Tina Vilsb{\o}ll and Knop, {Filip K}",
note = "Copyright {\circledC} 2019. Published by Elsevier Inc.",
year = "2019",
month = "11",
day = "1",
doi = "10.1016/j.peptides.2019.170178",
language = "English",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc",

}

RIS

TY - JOUR

T1 - GIP's involvement in the pathophysiology of type 2 diabetes

AU - Christensen, Mikkel B

AU - Gasbjerg, Lærke S

AU - Heimbürger, Sebastian M

AU - Stensen, Signe

AU - Vilsbøll, Tina

AU - Knop, Filip K

N1 - Copyright © 2019. Published by Elsevier Inc.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - During the past four decades derangements in glucose-dependent insulinotropic polypeptide (GIP) biology has been viewed upon as contributing factors to various parts of the pathophysiology type 2 diabetes. This overview outlines and discusses the impaired insulin responses to GIP as well as the effect of GIP on glucagon secretion and the potential involvement of GIP in obesity and bone disease associated with type 2 diabetes. As outlined in this review, it is unlikely that impaired insulinotropic effects of GIP occur as a primary event in the development of type 2 diabetes, but rather develop once the diabetic state is present and beta cells are unable to maintain normoglycemia. In various models, GIP has effects on glucagon secretion, bone and lipid homeostasis, but whether these effects contribute substantially to the pathophysiology of type 2 diabetes is at present controversial. The review also discusses the substantial uncertainty surrounding the translation of preclinical data relating to the GIP system and outline future research directions.

AB - During the past four decades derangements in glucose-dependent insulinotropic polypeptide (GIP) biology has been viewed upon as contributing factors to various parts of the pathophysiology type 2 diabetes. This overview outlines and discusses the impaired insulin responses to GIP as well as the effect of GIP on glucagon secretion and the potential involvement of GIP in obesity and bone disease associated with type 2 diabetes. As outlined in this review, it is unlikely that impaired insulinotropic effects of GIP occur as a primary event in the development of type 2 diabetes, but rather develop once the diabetic state is present and beta cells are unable to maintain normoglycemia. In various models, GIP has effects on glucagon secretion, bone and lipid homeostasis, but whether these effects contribute substantially to the pathophysiology of type 2 diabetes is at present controversial. The review also discusses the substantial uncertainty surrounding the translation of preclinical data relating to the GIP system and outline future research directions.

U2 - 10.1016/j.peptides.2019.170178

DO - 10.1016/j.peptides.2019.170178

M3 - Review

JO - Peptides

JF - Peptides

SN - 0196-9781

ER -

ID: 58295673